Sarah Cote
Nurse Practitioner · Windham, MENPI 1215225362
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Bayer at 25.3% of the total. Reporting peaked in 2022 at $1,037 and has fallen 80.0% since, to $208 in 2025. Among nurse practitioner clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $24.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$830
- Novo Nordisk$478
- Abbott$379
- Lilly USA, LLC$298
- AstraZeneca$291
- Medtronic$206
- plus $802 from 11 others
What the payments were for
- Food & beverage$3,17197%
- Education$532%
- Gifts$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 33 | $830 |
| Novo Nordisk | 19 | $478 |
| Abbott | 14 | $379 |
| Lilly USA, LLC | 17 | $298 |
| AstraZeneca | 7 | $291 |
| Medtronic | 9 | $206 |
| Merck | 9 | $151 |
| Insulet Corporation | 5 | $141 |
| Tandem Diabetes Care, Inc. | 8 | $129 |
| Dexcom, Inc. | 3 | $105 |
| Mannkind Corporation | 3 | $93 |
| Corcept Therapeutics | 2 | $59 |
| Boehringer Ingelheim | 2 | $38 |
| Cequr Corporation | 1 | $28 |
| BETA Bionics, Inc. | 1 | $22 |
| Sequel Med Tech, LLC | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$125
- RYBELSUS$125
- FARXIGA$121
- FreeStyle Libre$112
How this compares
$3,283 in reported general payments places this provider in the 95th percentile of 740 nurse practitioner providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 113 | $193,777 |
| JardianceEmpagliflozin | 139 | $166,420 |
| TrulicityDulaglutide | 76 | $116,394 |
| KerendiaFinerenone | 65 | $99,627 |
| MounjaroTirzepatide | 88 | $96,193 |
| Tresiba Flextouch U-200Insulin Degludec | 64 | $75,243 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 59 | $45,173 |
| Tresiba Flextouch U-100Insulin Degludec | 48 | $30,270 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 34 | $17,074 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 21 | $16,043 |
| RybelsusSemaglutide | 13 | $14,465 |
| Novolog FlexpenInsulin Aspart | 55 | $13,507 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 54 | $7,164 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $6,409 |
| Humalog Kwikpen U-100Insulin Lispro | 31 | $5,667 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Insulin Lispro | $298 | $214,254180 claims |
| Novo NordiskOzempic, Rybelsus | $478 | $208,242126 claims |
| Boehringer IngelheimJardiance | $38 | $166,420139 claims |
| BayerKerendia | $830 | $99,62765 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 740 nurse practitioner providers in Maine.
Other nurse practitioner in Windham
- Amanda MagnoliWestbrook$113K
- Gisele CastonguayLewiston$26K
- Rachel Koransky-MatsonBangor$16K
- Denise ViekmanPortland$15K
- Kerri NeelYork$5K
- Mallory EvansYork$5K
- Karrie SweetPortland$5K
- Noelle CooperSouth Portland$4K
- Kimberlee SmithKittery$3K
- Wenda CollienBelfast$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.